CNBC Investing Club: Cramer’s Morning Take on Microsoft 4/27/26

SPEAKER_1 (0:00)

Have you heard about the power of Neuro-Symbolic AI for business growth? EY Parthenon is the only organization with this innovative technology.

Neuro-Symbolic AI helps you find the growth pathways your competitors can't see by fusing pattern recognition with logic, rules and causal structures to uncover granular insights you can trust. Ready to use Neuro-Symbolic AI to capture exponential growth? Start today with EY Parthenon, solutions that work in practice, not just on paper.

SPEAKER_2 (0:29)

Trading at Schwab is powered by Ameritrade, giving you even more specialized support than ever before, like access to the trade desk. Our team of passionate traders ready to tackle anything from the most complex trading questions to a simple strategy gut check. Need assistance? No problem. Get 24-7 professional answers and live help, and access support by phone, email, and in-platform chat. That's how Schwab is here for you to help you trade brilliantly.

Learn more at schwab.com/trading.

Jim Cramer (0:59)

Jim Cramer here to share a short preview of my take on the market from today's Members Only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 10:20 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

Dan Ives (1:22)

We did get this amended agreement between Microsoft and OpenAI where Microsoft will remain OpenAI's primary cloud partner. But OpenAI can now serve all of its products to customers across any cloud provider. Initially, Microsoft is down a few percent off this.

Jim Cramer (1:40)

I question that. We know that Microsoft is not going to be paying OpenAI anything. It's just going to be receiving money from OpenAI. Thank you, Dan Ives.

Dan Ives (1:48)

Yeah, no longer paying a revenue share.

Jim Cramer (1:50)

One thing is certain. This stock was up a great deal, but it consolidated. Now, what does that mean for when it reports this week?

I have to tell you that they are announcing so many different things that indicate they are tightening their belts, that if they have any revenue growth, it could really surprise people.

Dan Ives (2:07)

Yeah, tightening belts in some areas. I think in others, they've been a little bit more aggressive recently in snapping up data center leases because the real bottleneck to Azure growth has been compute capacity. So if you can get more supply on, you can get a nice acceleration.

Jim Cramer (2:24)

Now, what do you think that means in terms of OpenAI being able to use now and be able to use Amazon? But also, I mean, to me, Microsoft's out of capacity so they can switch and put some stuff on Amazon could be good for OpenAI.

They think it is.

Dan Ives (2:37)

Sure. Yeah, it could be good for...

Jim Cramer (2:39)

Maybe it's one that both sides win. I don't know.

Dan Ives (2:41)

Yeah. Again, this came out at like around nine o'clock. So still working through it.

And of course, OpenAI is a big part of Azure's backlog as well. So I think there's just... Can't get enough compute still. So I think OpenAI shopping around, not a biggest surprise there. But I think really, just to go back to the Microsoft quarter, you need to see Azure acceleration to push back on some of the bears here.

SPEAKER_5 (3:11)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates, and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_6 (3:43)

Snoring, gasping during sleep, feeling fatigued? Ask your doctor about ZepBound Terzepatite, the first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea, OSA and adults with obesity. ZepBound is a prescription medicine used with a reduced calorie diet and increased physical activity to help adults with moderate to severe obstructive sleep apnea, OSA and obesity to improve their OSA. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5 or 15 milligram injection.

ZepBound contains terzepotide and should not be used with other terzepotide-containing products or any GLP-1 receptor agonist medicines. It is not known if ZepBound is safe and effective for use in children. Don't share needles or pins or reuse needles. Don't take if allergic to it or if you or someone in your family had medullary thyroid cancer or if you've had multiple endocrine neoplasia syndrome type 2 Tell your doctor if you get a lump or swelling in your neck. Stop ZepBound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experienced vision changes before scheduled procedures with anesthesia, if you're nursing, pregnant, planned to be or taking birth control pills. Taking ZepBound with a sulfonyluria or insulin may cause low blood sugar. Side effects include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems.